A Review of the Present State of Data for Metformin as a Geroprotective Drug
Researchers here review the present state of research and use of metformin as a geroprotective drug, intended to modestly slow aging. They are largely on point, if somewhat too accepting of the quality of the existing human data. While effective as a treatment for metabolic syndrome and type 2 diabetes, metformin is nowhere near as good a choice as rapamycin if forced to pick a geroprotective drug with modest effects on aging. For one, the animal data for effects on aging is very mixed, and there are sizeable methodological and other concerns regarding the human clinical trial evidence for reduced mortality and increased life expectancy. More recent human data tends to show little to no effect on that front.
Metformin is a biguanide and first line drug for type 2 diabetes (T2D) mellitus that is being recognized as a geroprotective agent capable of influencing important hallmarks of aging. Apart from its primary role in lowering blood glucose levels, metformin has been shown to have several effects at the molecular level. It acts by activating the AMPK, which leads to a cascade of downstream events such as the inhibition of mTOR, increased mitochondrial biogenesis, and autophagy, as well as epigenetic modifications. Current findings also showed its capacity to alter the gut microbiota by increasing short-chain fatty acid producing bacteria, indicating the involvement of other systemic pathways that aid in lowering inflammation, increasing metabolic fitness, and keeping epigenetic stability.
The Targeting Aging with Metformin (TAME) trial represents a landmark effort to evaluate metformin's efficacy in delaying the onset of chronic age-related diseases in non-diabetic individuals [28]. Designed as a multi-center, randomized, placebo-controlled trial, TAME seeks to enroll 3,000 individuals between the ages of 65 and 79 years and follow them for four years. By assessing biomarkers of aging and clinical endpoints across multiple age-related conditions such as cardiovascular events, cancer, cognitive decline, and all-cause mortality, TAME aims to validate metformin as a gerotherapeutic. However, since its start in 2017, no results have been published yet which make many to speculate that the trial may be on hold due to financial issues. In a 2025 interview, Dr. Nir Barzilai clarified that TAME is now handled by ARPA-H and could lead to two major trials with similar design but focused on GLP-1 agonist drugs.
The Metformin and Dietary Restriction to Prevent Age-Related Morbid Events in People with Metabolic Syndrome (MeMeMe) trial on the other hand evaluated the effects of metformin with or without dietary restriction on the development of major age-related diseases in over 1,400 participants aged 50-79 with metabolic syndromes. The trial found that 1700 mg/day of metformin was effective in preventing diabetes in people with metabolic syndromes. They reported an 80% and 92% reduction of type two diabetes in the metformin and the metformin and Mediterranean diet groups compared to the placebo group. However, no preventive effect was seen for cancer, cardiovascular diseases, and mortality.